PUBLISHER: The Business Research Company | PRODUCT CODE: 1458646
PUBLISHER: The Business Research Company | PRODUCT CODE: 1458646
Denosumab Global Market Report 2024
Denosumab is a monoclonal antibody employed in the treatment of bone-related conditions, particularly osteoporosis and bone metastases. Its mechanism of action involves inhibiting osteoclast formation, reducing bone resorption, increasing bone mineral density, and consequently lowering the risk of fractures.
The main classifications of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medicine specifically used for treating osteoporosis in postmenopausal women who are at a high risk of fractures or cannot use another osteoporosis medication. This drug is available in 60 mg and 120 mg doses and is utilized by various end-users such as hospitals, home care services, specialty clinics, and ambulatory surgical centers.
The denosumab market research report is one of a series of new reports from The Business Research Company that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth observed during the historic period can be attributed to various factors, including advancements in clinical trials and research, milestones achieved in FDA approvals and regulatory processes, a growing awareness of bone health, and the impact of strategic partnerships and effective marketing initiatives.
The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to factors such as the rising incidence of bone metastases, advancements in cancer therapies, the prevalence of osteoporosis, increased awareness of osteoporosis-related issues, and regulatory approvals for new indications. Major trends expected in the forecast period include strategic collaborations and partnerships within the pharmaceutical industry, integration with digital health solutions for improved patient care, expanded indications and clinical applications of denosumab, and advancements in biosimilar development for enhanced treatment options.
The rising prevalence of osteoporosis is anticipated to drive the expansion of the denosumab market in the coming years. Osteoporosis, characterized by weakened bones and diminished bone density, heightens the susceptibility to fractures. Denosumab, a medication targeting the RANK ligand, is utilized in the treatment of osteoporosis by halting bone resorption processes. As highlighted in a December 2023 report by the Australian Institute of Health and Welfare (AIHW), osteoporosis contributed to 2,366 fatalities in 2021, equating to 6.5 deaths per 100,000 individuals, constituting 1.4% of total deaths. Moreover, during 2021-22, there were 9,500 hospitalizations among individuals aged 45 and above with a primary diagnosis of osteoporosis, translating to 89 hospitalizations per 100,000 population. Thus, the escalating prevalence of osteoporosis acts as a catalyst for the growth of the denosumab market.
Key players within the denosumab market are intensifying their efforts to introduce innovative solutions, particularly first-line treatments for osteoporosis, to gain a competitive advantage. First-line treatment for osteoporosis denotes the initial therapeutic approach recommended by healthcare practitioners for managing individuals diagnosed with the condition. For instance, in November 2022, Boan Biotech, a China-based biotechnology firm, secured approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, becoming the first Chinese company to develop a denosumab injection. Boyoubei is also slated for introduction into markets beyond China, including Europe and the United States, with a global marketing strategy in place. Positioned as a first-line treatment option for osteoporosis in various treatment guidelines, Boyoubei holds promise in significantly reducing the risk of hip, non-vertebral, and vertebral fractures among affected individuals. Notably, Boyoubei stands out as the world's first biosimilar to Prolia (the originator of denosumab) to receive marketing approval.
In June 2022, Organon, a pharmaceutical company headquartered in the United States, entered into a partnership with Henlius to commercialize Henlius for an undisclosed sum. This collaboration enables Organon to obtain the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). The agreement aligns with Organon's expertise in biosimilar commercialization and its dedication to providing high-quality and cost-effective biologic medicines globally, with a specific focus on women's health. Henlius, a biopharmaceutical company based in China, specializes in the development of Denosumab biosimilars, including HLX14.
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited
North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Denosumab Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on denosumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for denosumab? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The denosumab market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
- 1) By Drug Classification: Prolia; Xgeva; Others
- 2) By Type: 60 mg; 120 mg
- 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Ambulatory Surgical Centers
- Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Novartis International AG; Sanofi SA; GlaxoSmithKline plc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Denosumab Market Characteristics
3. Denosumab Market Trends And Strategies
4. Denosumab Market - Macro Economic Scenario
- 4.1. Impact Of High Inflation On The Market
- 4.2. Ukraine-Russia War Impact On The Market
- 4.3. COVID-19 Impact On The Market
5. Global Denosumab Market Size and Growth
- 5.1. Global Denosumab Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
- 5.2. Global Denosumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
- 5.3. Global Denosumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Denosumab Market Segmentation
- 6.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Prolia
- Xgeva
- Others
- 6.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
60 mg
120 mg
- 6.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Ambulatory Surgical Centers
7. Denosumab Market Regional And Country Analysis
- 7.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 7.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Denosumab Market
- 8.1. Asia-Pacific Denosumab Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.3. Asia-Pacific Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 8.4. Asia-Pacific Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Denosumab Market
- 9.1. China Denosumab Market Overview
- 9.2. China Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.3. China Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
- 9.4. China Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Denosumab Market
- 10.1. India Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.2. India Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 10.3. India Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Denosumab Market
- 11.1. Japan Denosumab Market Overview
- 11.2. Japan Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.3. Japan Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 11.4. Japan Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Denosumab Market
- 12.1. Australia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.2. Australia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 12.3. Australia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Denosumab Market
- 13.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.2. Indonesia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 13.3. Indonesia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Denosumab Market
- 14.1. South Korea Denosumab Market Overview
- 14.2. South Korea Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.3. South Korea Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 14.4. South Korea Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Denosumab Market
- 15.1. Western Europe Denosumab Market Overview
- 15.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.3. Western Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 15.4. Western Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Denosumab Market
- 16.1. UK Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.2. UK Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 16.3. UK Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Denosumab Market
- 17.1. Germany Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.2. Germany Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 17.3. Germany Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Denosumab Market
- 18.1. France Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.2. France Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 18.3. France Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Denosumab Market
- 19.1. Italy Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.2. Italy Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 19.3. Italy Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Denosumab Market
- 20.1. Spain Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.2. Spain Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 20.3. Spain Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Denosumab Market
- 21.1. Eastern Europe Denosumab Market Overview
- 21.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.3. Eastern Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 21.4. Eastern Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Denosumab Market
- 22.1. Russia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.2. Russia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 22.3. Russia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Denosumab Market
- 23.1. North America Denosumab Market Overview
- 23.2. North America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.3. North America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 23.4. North America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Denosumab Market
- 24.1. USA Denosumab Market Overview
- 24.2. USA Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.3. USA Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 24.4. USA Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Denosumab Market
- 25.1. Canada Denosumab Market Overview
- 25.2. Canada Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.3. Canada Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 25.4. Canada Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Denosumab Market
- 26.1. South America Denosumab Market Overview
- 26.2. South America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.3. South America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 26.4. South America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Denosumab Market
- 27.1. Brazil Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.2. Brazil Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 27.3. Brazil Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Denosumab Market
- 28.1. Middle East Denosumab Market Overview
- 28.2. Middle East Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.3. Middle East Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 28.4. Middle East Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Denosumab Market
- 29.1. Africa Denosumab Market Overview
- 29.2. Africa Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.3. Africa Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
- 29.4. Africa Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Denosumab Market Competitive Landscape And Company Profiles
- 30.1. Denosumab Market Competitive Landscape
- 30.2. Denosumab Market Company Profiles
- 30.2.1. Johnson & Johnson
- 30.2.1.1. Overview
- 30.2.1.2. Products and Services
- 30.2.1.3. Strategy
- 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
- 30.2.2.1. Overview
- 30.2.2.2. Products and Services
- 30.2.2.3. Strategy
- 30.2.2.4. Financial Performance
- 30.2.3. Novartis International AG
- 30.2.3.1. Overview
- 30.2.3.2. Products and Services
- 30.2.3.3. Strategy
- 30.2.3.4. Financial Performance
- 30.2.4. Sanofi SA
- 30.2.4.1. Overview
- 30.2.4.2. Products and Services
- 30.2.4.3. Strategy
- 30.2.4.4. Financial Performance
- 30.2.5. GlaxoSmithKline plc
- 30.2.5.1. Overview
- 30.2.5.2. Products and Services
- 30.2.5.3. Strategy
- 30.2.5.4. Financial Performance
- 30.2.1. Johnson & Johnson
31. Denosumab Market Other Major And Innovative Companies
- 31.1. Eli Lilly and Company
- 31.2. Amgen Inc.
- 31.3. Asahi Kasei Corporation
- 31.4. Teva Pharmaceutical Industries Ltd.
- 31.5. Astellas Pharma Inc.
- 31.6. Daiichi Sankyo Company, Limited
- 31.7. Mylan N.V.
- 31.8. Sandoz International GmbH
- 31.9. Daiichi Sankyo Company Limited
- 31.10. Aurobindo Pharma Limited
- 31.11. Cipla Limited
- 31.12. Dr. Reddy's Laboratories Ltd.
- 31.13. Hikma Pharmaceuticals PLC
- 31.14. Celltrion Inc.
- 31.15. Amneal Pharmaceuticals Inc
32. Global Denosumab Market Competitive Benchmarking
33. Global Denosumab Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Denosumab Market
35. Denosumab Market Future Outlook and Potential Analysis
- 35.1 Denosumab Market In 2028 - Countries Offering Most New Opportunities
- 35.2 Denosumab Market In 2028 - Segments Offering Most New Opportunities
- 35.3 Denosumab Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
